Ustekinumab exposure and baseline covariates

90mg sc q8w reference

Prospective regular SC dosing from explicitly drug-free initial conditions; Table 1 reference priors.

Readouts

Central concentration · mg/L

Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.

Exposure (AUC) · mg*day/L

Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.

Clearance · L/day

Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.

Accounted amount · mg

Conditional model quantity; exposure and elimination integrals are added nonfeedback accounting readouts.

Study purpose

• How do the model's key biological readouts change under 90mg sc q8w reference?

Assumptions

• Table 1 reference-parameter PK projection; fixed priors are not individual posterior clearance estimates.
• Zero initial drug is a declared prospective assumption. The measured cohort had prior induction and at least 16 weeks therapy.
• Dose calendars are authored regular 90 mg SC schedules through the displayed interval; original patient dose histories are unavailable.
• No weight scaling is inferred from the current table; arbitrary weight-dependent individual predictions are unavailable.
• Antibody-positive status is an external-prior covariate exploration; all observed current-study cycles were antibody negative.
• Exposure and amount-accounting observers are derived additions and do not predict disease control.
• No cohort-median matching, statistical fitting, posterior inference, population sampling or clinical-response prediction is performed.